Moores Thomas Steven, Beaven Alastair, Cattell Andrew Edwin, Baker Charles, Roberts Philip John
Trauma and Orthopaedic Department, University Hospital of North Staffordshire, United Kingdom.
J Orthop Surg (Hong Kong). 2015 Apr;23(1):33-6. doi: 10.1177/230949901502300108.
To evaluate our hospital protocol of low-dose vitamin K titration for preoperative warfarin reversal for early hip fracture surgery.
Records of 16 men and 33 women aged 63 to 93 (mean, 81) years who were taking warfarin for atrial fibrillation (n=40), venous thromboembolism (n=9), cerebrovascular accident (n=3), and prosthetic heart valve (n=3) and underwent surgery for hip fractures were reviewed. The 3 patients with a prosthetic heart valve were deemed high risk for thromboembolism and the remainder low-risk. The international normalised ratio (INR) of patients was checked on admission and 6 hours after administration of vitamin K; an INR of <1.7 was considered safe for surgery.
No patient developed venous thromboembolism within one year. The 30-day and one-year mortality was 8.2% and 32.6%, respectively. For the 46 low-risk patients, the mean INR on admission was 2.6 (range, 1.1-4.6) and decreased to <1.7 after a mean of 2.2 (range, 0-4) administrations of 2 mg of vitamin K. Their INR was <1.7 within 18 hours (mean, 14 hours). 78% of patients underwent surgery within 36 hours. In the 22% of patients who did not undergo surgery within 36 hours, the delay was due to insufficient operative time or the patient being medically unfit for surgery. The 3 high-risk patients underwent bridging therapy of low-molecular-weight heparin and received no vitamin K; their mean INR on admission was 3.2 (range, 3.1-3.3) and the mean time to surgery was 5.3 (range, 3-8) days. Two low-risk patients and one high-risk patient died within 5 days of surgery.
The low-dose intravenous vitamin K protocol is safe and effective in reversing warfarin within 18 hours. Hip fracture surgery within 36 to 48 hours of admission improves morbidity and mortality.
评估我院针对早期髋部骨折手术,采用低剂量维生素K滴定法进行术前华法林逆转的方案。
回顾了16名男性和33名女性患者的记录,这些患者年龄在63至93岁(平均81岁),因心房颤动(n = 40)、静脉血栓栓塞(n = 9)、脑血管意外(n = 3)和人工心脏瓣膜(n = 3)而服用华法林,并接受了髋部骨折手术。3名人工心脏瓣膜患者被视为血栓栓塞高风险患者,其余为低风险患者。入院时及给予维生素K后6小时检查患者的国际标准化比值(INR);INR <1.7被认为手术安全。
一年内无患者发生静脉血栓栓塞。30天和一年死亡率分别为8.2%和32.6%。对于46名低风险患者,入院时平均INR为2.6(范围1.1 - 4.6),平均给予2.2次(范围0 - 4次)2mg维生素K后降至<1.7。他们的INR在18小时内(平均14小时)降至<1.7。78%的患者在36小时内接受了手术。在22%未在36小时内接受手术的患者中,延迟是由于手术时间不足或患者身体状况不适合手术。3名高风险患者接受了低分子量肝素桥接治疗,未接受维生素K;他们入院时平均INR为3.2(范围3.1 - 3.3),平均手术时间为5.3天(范围3 - 8天)。两名低风险患者和一名高风险患者在手术后5天内死亡。
低剂量静脉注射维生素K方案在18小时内逆转华法林是安全有效的。入院后36至48小时内进行髋部骨折手术可改善发病率和死亡率。